In the agreement with CoreValve, Medtronic will pay $700 million plus additional payments contingent on the achievement of agreed upon milestones. Medtronic will acquire Ventor for $325 million.
CoreValve is the developer of a transcatheter, transfemoral aortic valve replacement product. Ventor is the developer of two cardiovascular technologies — a minimally invasive, surgical transapical technology and a next-generation percutaneous, transfemoral technology.
Read the Medtronic news release on the acquisition of CoreValve.
Read the Medtronic news release on the acquisition of Ventor Technologies.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.